Shares of Ionis Pharmaceuticals IONS remained unaffected after the company reported Q4 results.
Quarterly Results
Earnings per share fell 39.10% over the past year to $0.81, which beat the estimate of $0.28.
Revenue of $290,000,000 decreased by 41.30% from the same period last year, which beat the estimate of $274,480,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Feb 24, 2021
Time: 09:00 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/952/39530
Price Action
Company's 52-week high was at $64.37
52-week low: $39.32
Price action over last quarter: Up 15.05%
Company Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.